{
    "clinical_study": {
        "@rank": "3043", 
        "arm_group": [
            {
                "arm_group_label": "Oxaloacetate (OAA)", 
                "arm_group_type": "Experimental", 
                "description": "active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo capsules that contain only 100 mg ascorbate, taken daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective\n      treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and\n      complete two safety follow-up phone calls over a 4 month period."
        }, 
        "brief_title": "A Pilot Study of Oxaloacetate in Subjects With Treated PD", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to give informed consent and follow instructions per the protocol\n\n          -  Diagnosis of idiopathic PD within 7 years of diagnosis\n\n          -  Taking stable doses of levodopa and would not predictably need adjustment in PD\n             medications for 4 months\n\n          -  Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at\n             baseline\n\n        Exclusion Criteria:\n\n          -  Previously taken Oxaloacetate\n\n          -  Participation in other drug studies or use of other investigational products within\n             30 days prior to baseline\n\n          -  In the Investigator's opinion, any unstable or clinically significant condition that\n             would impair the subjects' ability to comply with study follow-up\n\n          -  Other known or suspected cause of parkinsonism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741701", 
            "org_study_id": "13397"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oxaloacetate (OAA)", 
                "intervention_name": "Oxaloacetate (OAA)", 
                "intervention_type": "Drug", 
                "other_name": "benaGene\u2122"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "klyons@kumc.edu", 
                "last_name": "Kelly Lyons, PhD", 
                "phone": "913-588-7159"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }, 
            "investigator": {
                "last_name": "Rajesh Pahwa, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)", 
        "overall_contact": {
            "email": "klyons@kumc.edu", 
            "last_name": "Kelly Lyons, PhD", 
            "phone": "(913) 588-7159"
        }, 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Rajesh Pahwa, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate subject safety through data collection with various tests and procedures which include vital signs (blood pressure, heart rate, temperature, respiratory rate, height and weight), number of patients with adverse events and type of adverse events, laboratory blood tests (chem 12 metabolic panel, CBC with differential, serum/plasma amino acids).", 
            "measure": "safety profile of study drug", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741701"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kansas", 
            "investigator_full_name": "Rajesh Pahwa, MD", 
            "investigator_title": "Professor, Director PD and Movement Disorder Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Evaluate the efficacy of study drug based on change in PD from baseline to 4 months.  Includes Unified Parkinson's Disease Rating Scale, Hoehn & Yahr staging, Schwab and England, patient and clinician global impressions, PDQ-39 quality of life assessment, Montreal Cognitive Assessment, Geriatric Depression Scale, Nonmotor Symptoms Questionnaire.", 
            "measure": "efficacy of study drug", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "source": "University of Kansas", 
        "sponsors": {
            "collaborator": {
                "agency": "Terra Biological LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Kansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}